2025 was a pivotal year for cardiovascular medicine, marked by significant advancements and paradigm shifts in treatment and risk assessment. The field witnessed groundbreaking research and updated guidelines that reshaped clinical practices, offering new insights and approaches to managing cardiovascular health. Here's a breakdown of some of the most notable developments:
Aspirin Re-evaluated
One of the most significant shifts came from the re-evaluation of aspirin's role in cardiovascular health. Long-held assumptions about aspirin's benefits were challenged by new research released in 2025. The Medical Republic reported on several large studies, including findings that routine use of aspirin does not provide benefits that outweigh the substantially increased risks. Researchers concluded that lifelong aspirin use was based on outdated evidence, and superior antiplatelet therapies like clopidogrel are likely to replace aspirin as the preferred choice. A clinical trial even had to be halted early due to excess deaths, prompting clinicians to reconsider their prescribing practices. The study revealed that aspirin, when combined with anticoagulation therapy, failed to reduce the risk of stent thrombosis and, in fact, increased all-cause mortality by 72%.
Single Pill Combinations and Hypertension Treatment
2025 saw a strong push for single-pill combinations (SPCs) or fixed-dose combinations (FDCs) as first-line hypertension treatment. This led to urgent calls for changes to the Pharmaceutical Benefits Scheme (PBS) in Australia. However, despite the calls, the PBS restrictions have not been lifted, and updates to the Australian Hypertension Guidelines, expected at the end of 2025, have not been released yet.
CRISPR Gene Editing Breakthrough
Australian researchers made a significant breakthrough in CRISPR gene editing, with the first in-human trial successfully using gene-editing to manage cholesterol. A single injection of editing tools led to significant reductions in both cholesterol and triglycerides, marking the first therapy to achieve this simultaneously. This breakthrough is considered a potential game-changer for managing mixed lipid disorders.
Dyslipidaemia Management and Lipid-Lowering Regimens
The European Society of Cardiology and the European Atherosclerosis Society released new international recommendations for dyslipidaemia management. These guidelines proposed a more aggressive approach to lipid-lowering regimens, moving away from the traditional low and slow tactic. The recommendations emphasized the importance of utilizing Lp(a) for heart disease prevention, a long-overlooked risk factor. Research released in 2025 suggests that routine screening for Lp(a) could prevent a significant number of heart attacks, strokes, and early deaths.
PCSK9 Inhibitors and Cholesterol Management
The annual American Heart Association scientific sessions showcased multiple studies on PCSK9 inhibitors in cholesterol management, including a large trial of an oral version of the injectable medication. One study found that pairing PCSK9 inhibitors with statins provided additional protection, significantly reducing the risk of cardiovascular death, heart attack, or ischemic stroke by more than a quarter. Cardiologists from Italy, Germany, and the US, in a viewpoint published in the European Heart Journal, praised the impact of pivotal randomized clinical trials on interventional cardiology in 2025, highlighting their role in reshaping daily practice and refining long-term expectations for percutaneous therapies.
